Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug;68(8):530-537.
doi: 10.1007/s00101-019-00637-0.

[Considerations concerning the perioperative use of metamizole]

[Article in German]
R Sittl  1 , P Bäumler  1 , A-M Stumvoll  1 , D Irnich  2 , B Zwißler  3
Affiliations
Review

[Considerations concerning the perioperative use of metamizole]

[Article in German]
R Sittl et al. Anaesthesist. 2019 Aug.

Abstract

Background: The non-opioid analgesic metamizole (dipyrone) is approved for the treatment of severe pain and is often used in the perioperative period. As it can cause agranulocytosis, a severe adverse event, its perioperative administration is controversially discussed.

Objective: Is there enough evidence for a high risk of metamizol-induced agranulocytosis (MIA)? What are the consequences of its perioperative use with respect to the risk profiles of alternative analgesics?

Material and methods: Rapid review of the literature on the risk of MIA and adverse effects of non-opioid analgesics.

Results: The incidence of MIA is estimated to be one case per million inhabitants per year. The risk seems low compared to other drugs associated with a risk of agranulocytosis, such as antithyroid drugs and ticlopidine. The risk profile of metamizole concerning hepatotoxicity, nephrotoxicity, bleeding and cardiovascular adverse effects is favorable compared to other non-opioid analgesics. None of the non-opioid analgesics are licensed to be administered intraoperatively.

Conclusion: The perioperative use of metamizole is possible after a thorough evaluation of the indications as it provides good analgesia with a generally favorable side effect profile and is administered intravenously. The risk of agranulocytosis is small but needs to be mentioned during patient informed consent in order to optimize early recognition. Intraoperative administration aims at reducing the expected severe postoperative pain. A documentation and justification for the evaluation of the indications are recommended.

Keywords: Adverse events; Agranulocytosis; Dipyrone; Pain treatment; Review.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. J Clin Epidemiol. 1998 Dec;51(12):1357-65 - PubMed
    1. Int J Clin Pharmacol Ther. 1999 Apr;37(4):168-74 - PubMed
    1. Lancet. 1999 Jun 12;353(9169):2051-8 - PubMed
    1. Br J Surg. 1999 Dec;86(12):1528-31 - PubMed
    1. Anesthesiology. 2000 Oct;93(4):1123-33 - PubMed

LinkOut - more resources